Načítá se...
State‐of‐the‐art treatment of systemic lupus erythematosus
As glucocorticoids and immunosuppressive drugs are non‐specific therapeutic agents that cause many adverse reactions, the development of biologicals aiming to control specific molecular targets is anticipated for the treatment of systemic lupus erythematosus (SLE). The antibody targeting B cell‐acti...
Uloženo v:
| Vydáno v: | Int J Rheum Dis |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7187183/ https://ncbi.nlm.nih.gov/pubmed/32134201 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1756-185X.13817 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|